Skip to content

Intervention of compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome

Clinical study for Intervention of compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026545
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-10-13
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patients with acute myocardial infarction within 12 hours, underwent emergency PCI, or underwent PCI after emergency thrombolytic therapy; 2. The patients meet the syndrome differentiation standard of TCM with Deficient Qi and Yin combined blood stasis; 3. Aged 18 to 75 years, both men and women; 4. Sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Stable angina or unstable angina; 2. Acute myocardial infarction with heart failure, Killip classification II, III or IV; 3. Acute myocardial infarction with severe complications, such as cardiogenic shock(conventional treatment cannot correct), or mechanical complication; 4. Severe arrhythmia, such as Rapid atrial fibrillation, ventricular tachycardia, high atrioventricular block, etc. 5. Chronic heart failure or old myocardial infarction in the past medical history; 6. Combined with other diseases, such as cardiomyopathy, rheumatic heart disease, severe valvular heart disease, cardiac tamponade, hypertension emergency, pulmonary arterial hypertension, acute paroxysmal asthma /COPD, severe infection , and so on; 7. Patients with severe liver and kidney function impairment (ALT >3 times the upper limit of normal reference value, or Cr >= 3mg/dL or eGFR<= 60ml/min1.73m2); and with severe primary diseases such as endocrine or hematopoietic system; and with mental diseases; 8. Patients with malignant tumor; 9. Allergic constitution or allergy to multiple drug or food, allergy to known components of the study drugs; 10. Cannot take care of themselves and cannot receive oral drug; 11. Participated in other drug clinical trials within 3 month; 12. Suspecting or ensuring with a history of substance abuse alcohol or drug abuse; 13. Pregnant or lactating women, or planned pregnancy; 14. Patients with cerebral vascular accidents, major surgery and trauma recently.

Design outcomes

Primary

MeasureTime frame
The Incidence of Heart failure;

Secondary

MeasureTime frame
type B natriuretic peptide(BNP);Echocardiography;6-min walk test (6-MWT);hypersensitive C reactive protein;traditional Chinese medicine(TCM) syndrome score;Minnesota questionnaire;Major adverse cardiovascular events (MACEs);

Countries

China

Contacts

Public ContactWu Wei

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

452124069@qq.com+86 13570211913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026